Sustained rapamycin drug delivery system in prevention of high risk corneal allograft rejection and neovascularization in rabbits

Chinese Journal of Ophthalmology

Volumn 42, Issue 1, 2006, Pages 6-11

  Gao, Hua ^a   Shi, Wei Yun ^a   Xie, Li Xin ^a   Wang, Shen Guo ^a  

^a Shangdong Eye Institute   (China)

Author keywords

Corneal neovascularization; Corneal transplantation; Delayed action preparations; Graft rejection; Sirolimus

Indexed keywords

EYE DROPS; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYCAPROLACTONE; POLYGLACTIN; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ANTIANGIOGENIC ACTIVITY; AQUEOUS HUMOR; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA STROMA; CORNEA VASCULARIZATION; DRUG DELIVERY SYSTEM; DRUG TISSUE LEVEL; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY; LIVER; NONHUMAN; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RABBIT; RETINA; RISK ASSESSMENT; SLIT LAMP; SURVIVAL; SUSTAINED RELEASE PREPARATION; SUTURE;

ANIMALS; CORNEAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; RABBITS; SIROLIMUS;

EID: 33644549676     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Weisbrod DJ, Sit M, Naor J, et al. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea, 2003, 22:429-434.
2. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol, 1999, 10:1366-1380.
3. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther, 2000, 22: 101-121.
4. Mills RA, Jones DB, Winkler CR, et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea, 1995, 14:157-160.
5. Holland EJ, Chan CC, Wetzig RP, et al. Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea, 1991, 10:374-380.
6. Wright DC, Deol HS, Tuch BE. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transpl Immunol, 1999, 7:141-147.
7. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation, 2002, 27: 920-925.
8. Xie LX, Shi WY, Wang Z, et al. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea, 2001, 20:748-752.
9. Reis A, Megahed M, Reinhard T, et al. Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea, 2002, 21:81-84.
10. Morelon E, Mamzer-Bruneel MF, Peraldi MN, et al. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant, 2001, 16:18-20.
11. Guba M, von Breitenbuch P, Steinbauer M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 2002, 8:128-135.
12. Chinese source. 2004, 40: 108-112.
13. Xie LX, Sun J, Yao Z. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes. Graefes Arch Clin Exp Ophthalmol, 2003, 241:309-313.